Thyroid cancer targeted therapy expands across differentiated, medullary, and anaplastic subtypes
RET inhibitor maturity, NTRK fusion-targeted use, BRAF V600E and MEK combinations in anaplastic disease, and emerging mechanism programs are restructuring thyroid cancer therapy.
Thyroid cancer was a surgery-and-radioiodine category for differentiated disease and a limited-options category for advanced and anaplastic disease. RET inhibitors (selpercatinib, pralsetinib) have matured in RET-altered disease, NTRK fusion-targeted therapy is routinely used in NTRK-fusion-positive thyroid cancer, BRAF V600E plus MEK combination (dabrafenib plus trametinib) is now standard in BRAF V600E-mutant anaplastic thyroid cancer, and emerging programs in radioiodine-refractory differentiated and aggressive variants are reading out. The biomarker-pathway investment defines the addressable population.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.